Abecma sales disappoint again as BCMA competition ramps up, FDA adcomm looms
Fourth-quarter US sales of Bristol Myers Squibb’s BCMA-targeting CAR-T therapy Abecma last year declined by 40% compared to the same period in 2022, primarily due to competitive pressure.
Abecma pulled in $56 million in US revenue and $100 million total worldwide, BMS reported in its earnings update Friday, figures that represented 40% and 20% drops, respectively. Competition from other BCMA-targeting drugs drove the decline, a company spokesperson told Endpoints News.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.